Ironwood Pharma (IRWD) Tops Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2017 Investor Update
February 15, 2018 8:01 AM ESTGenerated 2017 revenue of $298 million, driven primarily by LINZESS® (linaclotide) U.S. net sales of $701 million and expansion of LINZESS commercial margin to 61%
On track to advance key pipeline candidates in 2018, including Phase III trials for IW-3718 and LINZESS and Phase II trials for praliciguat (IW-1973) and IW-1701
Expect to generate positive cash flow in 4Q 2018 through continued top-line growth and financial discipline
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
